- Home
- BH vs AVBP Comparison
BH vs AVBP Comparison
Compare BH & AVBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BH
- AVBP
- Stock Information
- Founded
- BH 1934
- AVBP 2021
- Country
- BH United States
- AVBP United States
- Employees
- BH N/A
- AVBP N/A
- Industry
- BH Restaurants
- AVBP
- Sector
- BH Consumer Discretionary
- AVBP
- Exchange
- BH Nasdaq
- AVBP NYSE
- Market Cap
- BH 904.4M
- AVBP 862.8M
- IPO Year
- BH N/A
- AVBP 2024
- Fundamental
- Price
- BH $294.30
- AVBP $21.63
- Analyst Decision
- BH
- AVBP Strong Buy
- Analyst Count
- BH 0
- AVBP 8
- Target Price
- BH N/A
- AVBP $38.38
- AVG Volume (30 Days)
- BH 19.1K
- AVBP 484.4K
- Earning Date
- BH 08-08-2025
- AVBP 08-13-2025
- Dividend Yield
- BH N/A
- AVBP N/A
- EPS Growth
- BH N/A
- AVBP N/A
- EPS
- BH N/A
- AVBP N/A
- Revenue
- BH $367,698,000.00
- AVBP N/A
- Revenue This Year
- BH N/A
- AVBP $85.82
- Revenue Next Year
- BH N/A
- AVBP N/A
- P/E Ratio
- BH N/A
- AVBP N/A
- Revenue Growth
- BH 0.85
- AVBP N/A
- 52 Week Low
- BH $159.69
- AVBP $15.47
- 52 Week High
- BH $308.62
- AVBP $36.37
- Technical
- Relative Strength Index (RSI)
- BH 63.50
- AVBP 47.74
- Support Level
- BH $282.42
- AVBP $19.71
- Resistance Level
- BH $308.62
- AVBP $22.32
- Average True Range (ATR)
- BH 9.09
- AVBP 1.32
- MACD
- BH -0.56
- AVBP -0.20
- Stochastic Oscillator
- BH 46.37
- AVBP 31.89
About BH Biglari Holdings Inc. Class B
Biglari Holdings Inc is a holding company that owns subsidiaries in a range of businesses. The company's reportable segments include Restaurant Operations, Insurance Operations, Oil and Gas Operations. Company's restaurant operations include Steak n Shake and Western Sizzlin. Its insurance operations include First Guard, Southern Pioneer, and Biglari Reinsurance. Oil and gas operations include Southern Oil and Abraxas Petroleum. The Company also reports segment information for Maxim. The majority of revenue is derived from the Maxim Segment.
About AVBP ARRIVENT BIOPHARMA INC
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.